Finance
KKR makes $1.2 billion offer for Sweden's Biotage
Published by Global Banking & Finance Review®
Posted on April 22, 2025
1 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on April 22, 2025
1 min readLast updated: January 24, 2026
KKR has made a $1.2 billion offer for Biotage, with a 60.1% premium. Biotage's board recommends acceptance, with Gamma Biosciences owning a 17% stake.
COPENHAGEN (Reuters) -Sweden's Biotage said on Tuesday that KKR had made a cash offer for the Swedish biotechnology firm, valuing it at around 11.6 billion Swedish crowns ($1.22 billion).
The offer price of 145 crowns per share represents a premium of 60.1% compared with its closing share price on April 17.
Biotage's board of directors unanimously recommended to its shareholders that they accept the offer, the company said in a statement.
Gamma Biosciences, which is controlled by KKR, is the company's biggest shareholder owning a 17% stake.
($1 = 9.5059 Swedish crowns)
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
The article discusses KKR's $1.2 billion cash offer for Sweden's Biotage, highlighting the strategic implications for shareholders.
The offer represents a 60.1% premium compared to Biotage's closing share price on April 17.
Gamma Biosciences, controlled by KKR, is Biotage's biggest shareholder with a 17% stake.
Explore more articles in the Finance category
